Scadden David 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jul 15, 2025
Insider Transaction Report
Form 4
Scadden David
Director
Transactions
- Exercise/Conversion
Common stock
2025-07-10$18.09/sh+1,400$25,326→ 19,003 total - Sale
Common stock
2025-07-10$40.00/sh−1,400$56,000→ 17,603 total - Exercise/Conversion
Stock options (right to buy)
2025-07-10−1,400→ 27,707 totalExercise: $18.09Exp: 2032-06-21→ Common stock (1,400 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.